BioSpace News Archive

InDex Pharmaceuticals Holding AB (publ) today announced that the Swedish Medical Products Agency (MPA) has given approval to start the phase III clinical study CONCLUDE in Sweden.

OpenEye Scientific, developer of the world’s only cloud-native molecular design platform, Orion,™ announced today that it is among the first of only a handful of companies globally that have achieved Amazon Web Services (AWS) High Performance Computing (HPC) Competency status.

TRACON Pharmaceuticals (NASDAQ: TCON) (“TRACON” or the “Company”), today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co. under which the underwriter has agreed to purchase on a firm commitment basis 2,617,802 shares of the Company’s common stock at a public offering price of $3.82 per share, less underwriting discounts and commissions.

Ascletis Pharma Inc. (HKEX code: 1672) today announces that China National Medical Products Administration (NMPA) has approved the Phase III clinical trial application of ASC40 combined with Bevacizumab for treatment of patients with recurrent glioblastoma (rGBM).

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK), today announced that the Bellberry Human Research Ethics Committee (HREC) in Australia has approved the clinical trial application of the phase 1 trial of ATG-101 in patients with metastatic/advanced solid tumors and B-cell non-Hodgkin’s lymphoma (B-NHL)

TRACON Pharmaceuticals announced that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 3,926,702 shares of common stock of the Company at a price to the public of $3.82 per share, less underwriting discounts and commissions.

LEXEO Therapeutics today announced that it has acquired Stelios Therapeutics, an early-stage company developing novel adeno-associated virus (AAV)-mediated gene therapies for rare genetic cardiac conditions.

Esker Therapeutics today announced the appointment of several new team members: Kimberly Lindstorm, Ph.D., as vice president, regulatory. Travis Remarchuk, Ph.D., as executive director, CMC. Zhengbin (Bing) Yao, Ph.D., as a member of the board of directors.

Royal Phillips announced the FDA has granted Breakthrough Device Designation for a laser assisted inferior vena cava filter removal device.

Synaptogenix, Inc. today announced that it will hold a conference call for investors to discuss its abstract presented at the Alzheimer’s Association International Conference.